Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Author: Benzinga Newsdesk | April 29, 2024 07:01am
Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for PM359, submitted on March 29, for the treatment of chronic granulomatous disease (CGD), enabling the Company to initiate its global Phase 1/2 clinical trial in the United States.
Posted In: PRME